A mouse model for testing remyelinating therapies
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Used in combination with immunomodulatory therapies, remyelinating therapies are a viable therapeutic approach for treating individuals with multiple sclerosis. Studies of postmortem MS brains identified greater remyelination in demyelinated cerebral cortex than in demyelinated brain white matter and implicated reactive astrocytes as an inhibitor of white matter remyelination. An animal model that recapitulates these phenotypes would benefit the development of remyelination therapeutics. We have used a modified cuprizone protocol that causes a consistent and robust demyelination of mouse white matter and cerebral cortex. Spontaneous remyelination occurred significantly faster in the cerebral cortex than in white matter and reactive astrocytes were more abundant in white matter lesions. Remyelination of white matter and cerebral cortex was therapeutically enhanced by daily injections of thyroid hormone triiodothronine (T3). In summary, we describe an in vivo demyelination/remyelination paradigm that can be powered to determine efficacy of therapies that enhance white matter and cortical remyelination.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766 · cited 1×
“In this respect, it is interesting to note that long-term (1–2 years) daily feeding of rapamycin to adult mice significantly increases lifespan of both male and female mice (Harrison et al., 2009).”
BackgroundCortical demyelination and diffuse white matter injury in multiple sclerosis
Kutzelnigg, A., Lucchinetti, C. F., Stadelmann, C., Brück, W., Rauschka, H., Bergmann, M., Schmidbauer, M., Parisi, J. E., & Lassmann, H. (2005) · Brain · doi:10.1093/brain/awh641 · Cited by 1,836
Remyelination in the CNS: from biology to therapy
Franklin, R. J. M., & ffrench-Constant, C. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2480 · Cited by 1,544 · cited 3×
“…of remyelination of large diameter axons (Michailov et al., 2004), the use of g-ratio as an indicator of remyelination of small diameter axons in the corpus callosum has been controversial (Franklin and Ffrench-Constant, 2008; Klopfleisch et al., 2008; Mason et al., 2001; Moore et Exp Neurol.”
BackgroundMethodMatsushima, G. K., & Morell, P. (2001) · Brain Pathology · doi:10.1111/j.1750-3639.2001.tb00385.x · Cited by 984 · cited 3×
“Factors contributing to the variation include genetics (species, age etc), treatment paradigms and readouts (Gudi et al., 2009; Hiremath et al., 2008; Matsushima and Morell, 2001a; Skripuletz et al., 2008; Taylor et al., 2009).”
BackgroundMyelin Impairs CNS Remyelination by Inhibiting Oligodendrocyte Precursor Cell Differentiation
Kotter, M. R., Li, W.-W., Zhao, C., & Franklin, R. J. M. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2615-05.2006 · Cited by 768
Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis
Trapp, B. D., & Stys, P. K. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70043-2 · Cited by 621 · cited 1×
“Degeneration of demyelinated axons is a major cause of permanent neurological disability in individuals with MS. Remyelination restores saltatory conduction and provides trophic support that enhances axon survival (Crawford et al., 2009; Duncan et al., 2009; Trapp and Stys, 2009).”
BackgroundSelf-citationHyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation
Back, S. A., Tuohy, T. M. F., Chen, H., Wallingford, N., Craig, A., Struve, J., Luo, N. L., Banine, F., Liu, Y., Chang, A., et al. (2005) · Nature Medicine · doi:10.1038/nm1279 · Cited by 612 · cited 3×
“…activation of astrocytes and microglia, and increased levels of hyaluronan and hyaluronan-binding membrane protein following 12 weeks of cup/rap demyelination of white matter compared to gray matter, similar to what was described in postmortem MS brains (Back et al., 2005; Chang et al., 2012).”
BackgroundResultSelf-citationPathophysiology of the brain extracellular matrix: a new target for remyelination
Lau, L. W., Cua, R., Keough, M. B., Haylock-Jacobs, S., & Yong, V. W. (2013) · Nature reviews. Neuroscience · doi:10.1038/nrn3550 · Cited by 549 · cited 2×
“…proposed that the decreased rate of white matter remyelination in MS brains was influenced by reactive astrocytes which secrete and organize extracellular matrix proteins that inhibit oligodendrocyte differentiation and myelination (Lau et al., 2013; Ponta et al., 2003; Sherman and Back, 2008).”
BackgroundRetinoid X receptor gamma signaling accelerates CNS remyelination
Huang, J. K., Jarjour, A. A., Nait Oumesmar, B., Kerninon, C., Williams, A., Krezel, W., Kagechika, H., Bauer, J., Zhao, C., Evercooren, A. B.-V., et al. (2011) · Nature Neuroscience · doi:10.1038/nn.2702 · Cited by 547
A regenerative approach to the treatment of multiple sclerosis
Deshmukh, V. A., Tardif, V., Lyssiotis, C. A., Green, C. C., Kerman, B., Kim, H. J., Padmanabhan, K., Swoboda, J. G., Ahmad, I., Kondo, T., et al. (2013) · Nature · doi:10.1038/nature12647 · Cited by 531
TREM2 sustains microglial expansion during aging and response to demyelination
Poliani, P. L., Wang, Y., Fontana, E., Robinette, M. L., Yamanishi, Y., Gilfillan, S., & Colonna, M. (2015) · Journal of Clinical Investigation · doi:10.1172/jci77983 · Cited by 525 · cited 1×
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript al., 2014; Poliani et al., 2015; Stidworthy et al., 2003).”
BackgroundSteinman, L., & Zamvil, S. S. (2006) · Annals of Neurology · doi:10.1002/ana.20913 · Cited by 479
Differentiation and death of premyelinating oligodendrocytes in developing rodent brain
Trapp, B. D., Nishiyama, A., Cheng, D., & Macklin, W. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.137.2.459 · Cited by 395 · cited 2×
“1% Triton X-100 and stained by the avidin-biotin complex (ABC) procedure and diaminobenzedine as described previously (Trapp et al., 1997).”
MethodSelf-citationSkripuletz, T., Hackstette, D., Bauer, K., Gudi, V., Pul, R., Voss, E., Berger, K., Kipp, M., Baumgärtner, W., & Stangel, M. (2013) · Brain · doi:10.1093/brain/aws262 · Cited by 376
Constitutively active Akt induces enhanced myelination in the CNS
Flores, A. I., Narayanan, S. P., Morse, E. N., Shick, H. E., Yin, X., Kidd, G., Avila, R. L., Kirschner, D. A., & Macklin, W. B. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.0150-08.2008 · Cited by 361
Self-citationIdentification of a microglia phenotype supportive of remyelination
Olah, M., Amor, S., Brouwer, N., Vinet, J., Eggen, B., Biber, K., & Boddeke, H. W. G. M. (2012) · Glia · doi:10.1002/glia.21266 · Cited by 358 · cited 4×
“For example, cuprizone treatment for 4, 5, 6, and 7 to12 weeks has been employed and has resulted in different levels of demyelination/ remyelination (Deshmukh et al., 2013; Kang et al., 2012; Moharregh-Khiabani et al., 2010; Olah et al., 2012; Schmidt et al., 2013; Skripuletz et al., 2012; Steelman et al., 2012).”
BackgroundInfluentialCharles, P., Hernandez, M. P., Stankoff, B., Aigrot, M. S., Colin, C., Rougon, G., Zalc, B., & Lubetzki, C. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.100076197 · Cited by 306 · cited 1×
“For example, surface protein polysialylated-neural cell adhesion molecule (PSA-NCAM), which is expressed at high levels in chronic MS Lesions (Charles et al., 2002, 2000), may inhibit myelin sheet formation during remyelination.”
BackgroundMi, S., Miller, R. H., Tang, W., Lee, X., Hu, B., Wu, W., Zhang, Y., Shields, C. B., Zhang, Y., Miklasz, S., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21581 · Cited by 300 · cited 1×
“Blocking LINGO-1 function appears to promote CNS remyelination in both slice culture systems and in mouse models (Mi et al., 2009).”
BackgroundRemyelination in Experimental Models of Toxin-Induced Demyelination
Blakemore, W. F., & Franklin, R. J. M. (2008) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-540-73677-6_8 · Cited by 275
Cortical Demyelination Is Prominent in the Murine Cuprizone Model and Is Strain-Dependent
Skripuletz, T., Lindner, M., Kotsiari, A., Garde, N., Fokuhl, J., Linsmeier, F., Trebst, C., & Stangel, M. (2008) · The American Journal of Pathology · doi:10.2353/ajpath.2008.070850 · Cited by 271 · cited 3×
“Factors contributing to the variation include genetics (species, age etc), treatment paradigms and readouts (Gudi et al., 2009; Hiremath et al., 2008; Matsushima and Morell, 2001a; Skripuletz et al., 2008; Taylor et al., 2009).”
BackgroundRegional differences between grey and white matter in cuprizone induced demyelination
Gudi, V., Moharregh-Khiabani, D., Skripuletz, T., Koutsoudaki, P. N., Kotsiari, A., Skuljec, J., Trebst, C., & Stangel, M. (2009) · Brain Research · doi:10.1016/j.brainres.2009.06.005 · Cited by 260 · cited 2×
“Factors contributing to the variation include genetics (species, age etc), treatment paradigms and readouts (Gudi et al., 2009; Hiremath et al., 2008; Matsushima and Morell, 2001a; Skripuletz et al., 2008; Taylor et al., 2009).”
BackgroundExtensive remyelination of the CNS leads to functional recovery
Duncan, I. D., Brower, A., Kondo, Y., Curlee, J. F., & Schultz, R. D. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812500106 · Cited by 227
Quantifying the early stages of remyelination following cuprizone-induced demyelination
Stidworthy, M. F., Genoud, S., Suter, U., Mantei, N., & Franklin, R. J. M. (2003) · Brain Pathology · doi:10.1111/j.1750-3639.2003.tb00032.x · Cited by 224
Cortical remyelination: A new target for repair therapies in multiple sclerosis
Chang, A., Staugaitis, S. M., Dutta, R., Batt, C. E., Easley, K. E., Chomyk, A. M., Yong, V. W., Fox, R. J., Kidd, G. J., & Trapp, B. D. (2012) · Annals of Neurology · doi:10.1002/ana.23693 · Cited by 216 · cited 7×
“3L), similar to what was observed in MS lesions (Chang et al., 2012).”
BackgroundResultSelf-citationSteelman, A. J., Thompson, J. P., & Li, J. (2012) · Neuroscience Research · doi:10.1016/j.neures.2011.10.002 · Cited by 183
Armstrong, R. C., Le, T. Q., Frost, E. E., Borke, R. C., & Vana, A. C. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-19-08574.2002 · Cited by 178 · cited 1×
“Heterogeneity of demyelination in corpus callosum and inter-animal variability have limited the utility of the cuprizone model (Armstrong et al., 2002; Stidworthy et al., 2003).”
BackgroundMason, J. L., Langaman, C., Morell, P., Suzuki, K., & Matsushima, G. K. (2001) · Neuropathology and Applied Neurobiology · doi:10.1046/j.0305-1846.2001.00301.x · Cited by 172
A ‘GAG’ reflex prevents repair of the damaged CNS
Sherman, L. S., & Back, S. A. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2007.11.001 · Cited by 116 · cited 1×
“…proposed that the decreased rate of white matter remyelination in MS brains was influenced by reactive astrocytes which secrete and organize extracellular matrix proteins that inhibit oligodendrocyte differentiation and myelination (Lau et al., 2013; Ponta et al., 2003; Sherman and Back, 2008).”
BackgroundTaylor, L. C., Gilmore, W., & Matsushima, G. K. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00230.x · Cited by 101 · cited 1×
“Factors contributing to the variation include genetics (species, age etc), treatment paradigms and readouts (Gudi et al., 2009; Hiremath et al., 2008; Matsushima and Morell, 2001a; Skripuletz et al., 2008; Taylor et al., 2009).”
BackgroundFunctional recovery of callosal axons following demyelination: A critical window
Crawford, D. K., Mangiardi, M., Xia, X., López-Valdés, H. E., & Tiwari-Woodruff, S. K. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.09.069 · Cited by 97
Negative Impact of Statins on Oligodendrocytes and Myelin Formation In Vitro and In Vivo
Klopfleisch, S., Merkler, D., Schmitz, M., Klöppner, S., Schedensack, M., Jeserich, G., Althaus, H. H., & Brück, W. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.2765-08.2008 · Cited by 97
Dietary Vitamin D3 Supplements Reduce Demyelination in the Cuprizone Model
Wergeland, S., Torkildsen, Ø., Myhr, K.-M., Aksnes, L., Mørk, S. J., & Bø, L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026262 · Cited by 88 · cited 2×
“In some reports, histological evaluations are supported by qualitative assessment of myelinated axons in electron micrographs (Deshmukh et al., 2013; Kang et al., 2012; Koutsoudaki et al., 2010; Larsen et al., 2006; Liu et al., 2010; Mi et al., 2011; Moharregh-Khiabani et al., 2010; Olah et al., 2012; Schmidt et al.,…”
BackgroundIL-17-Induced Act1-Mediated Signaling Is Critical for Cuprizone-Induced Demyelination
Kang, Z., Liu, L., Spangler, R., Spear, C., Wang, C., Gulen, M. F., Veenstra, M., Ouyang, W., Ransohoff, R. M., & Li, X. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.0841-12.2012 · Cited by 78
MHC class II exacerbates demyelination in vivo independently of T cells
Hiremath, M. M., Chen, V. S., Suzuki, K., Ting, J. P.-Y., & Matsushima, G. K. (2008) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2008.06.034 · Cited by 77 · cited 1×
“Factors contributing to the variation include genetics (species, age etc), treatment paradigms and readouts (Gudi et al., 2009; Hiremath et al., 2008; Matsushima and Morell, 2001a; Skripuletz et al., 2008; Taylor et al., 2009).”
BackgroundBlakemore, W. F. (1974) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(74)90059-8 · Cited by 72
Schmidt, T., Awad, H., Slowik, A., Beyer, C., Kipp, M., & Clarner, T. (2013) · Journal of Molecular Neuroscience · doi:10.1007/s12031-012-9896-0 · Cited by 49 · cited 5×
“For example, cuprizone treatment for 4, 5, 6, and 7 to12 weeks has been employed and has resulted in different levels of demyelination/ remyelination (Deshmukh et al., 2013; Kang et al., 2012; Moharregh-Khiabani et al., 2010; Olah et al., 2012; Schmidt et al., 2013; Skripuletz et al., 2012; Steelman et al., 2012).”
BackgroundInfluentialKoutsoudaki, P. N., Hildebrandt, H., Gudi, V., Skripuletz, T., Škuljec, J., & Stangel, M. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.08.070 · Cited by 37
Cited by
Remyelination therapies: a new direction and challenge in multiple sclerosis
Plemel, J. R., Liu, W.-Q., & Yong, V. W. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.115 · Cited by 281
Ferroptosis Mediates Cuprizone-Induced Loss of Oligodendrocytes and Demyelination
Jhelum, P., Santos-Nogueira, E., Teo, W., Haumont, A., Lenoël, I., Stys, P. K., & David, S. (2020) · The Journal of Neuroscience · doi:10.1523/jneurosci.1749-20.2020 · Cited by 214
Five Decades of Cuprizone, an Updated Model to Replicate Demyelinating Diseases
Vega-Riquer, J. M., Mendez-Victoriano, G., Morales-Luckie, R. A., & Gonzalez-Perez, O. (2019) · Current Neuropharmacology · doi:10.2174/1570159x15666170717120343 · Cited by 188
Ferroptosis induces detrimental effects in chronic EAE and its implications for progressive MS
Jhelum, P., Zandee, S., Ryan, F., Zarruk, J. G., Michalke, B., Venkataramani, V., Curran, L., Klement, W., Prat, A., & David, S. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01617-7 · Cited by 49
Yamate-Morgan, H., Lauderdale, K., Horeczko, J., Merchant, U., & Tiwari-Woodruff, S. K. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.01.038 · Cited by 27
“Compelled by the prospect of achieving more complete demyelination within our model, in a recent evaluation of a therapeutic agent, we included rapamycin as advised by the current literature (Narayanan et al., 2009; Sachs et al., 2014; Bai et al., 2016).”
BackgroundMethodInfluential
Metadata
- Authors
- Bai, C. B., Sun, S., Roholt, A., Benson, E., Edberg, D., Medicetty, S., Dutta, R., Kidd, G., Macklin, W. B., & Trapp, B.
- Venue
- Experimental Neurology
- Publisher
- Elsevier BV
- Published
- 2016-09
- Volume
- 283
- Issue
- Pt A
- Pages
- 330-340
- ISSN
- 0014-4886 (ISSN-L)
- OpenAlex
- W2470033627
- Cited by
- 65
- References
- 37
- FWCI
- 4.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.